Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02)
Feng‐Hua Wang(Sun Yat-sen University), Rui‐Hua Xu(Sun Yat-sen University), Yi Jiang(Nanjing University of Chinese Medicine), Sheng Yao(BioReliance (United States)), Lin Shen(Peking University), Yongqian Shu(Jiangsu Province Hospital), Yunpeng Liu(Capital Medical University), Qi Li(Zhejiang Cancer Hospital), Ye Chen(Hebei Medical University), Weifeng Wang(Unimed Medical Institute), Xiaoyan Lin(Fujian Medical University), Jifeng Feng(Zhejiang Cancer Hospital), Qingyuan Zhang(Jiangxi University of Traditional Chinese Medicine), Jianhua Shi(Linyi People's Hospital), Haixin Huang(Liuzhou Maternal and Child Health Hospital), Guanghai Dai(Chinese PLA General Hospital), Xianglin Yuan(Tongji Hospital), Xiaoli Wei(Anhui Medical University), Xichun Hu(Fudan University Shanghai Cancer Center), Hai Wu, Shujun Yang(Henan Cancer Hospital), Hui Feng(Boston University), Nong Xu(First Affiliated Hospital Zhejiang University), Wangjun Liao(Sun Yat-sen University)
Cited by 350
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
|The Lancet Oncology|2015|1.6k
Circular RNA: metabolism, functions and interactions with proteins
|Molecular Cancer|2020|1.6k
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
|Journal of Clinical Oncology|2020|1.2k